SBC Medical Group Holdings Incorporated is a management company headquartered in Irvine California and Tokyo Japan that owns operates and provides management services to cosmetic treatment centers mainly in Japan The company also owns and operates one treatment center in Ho Chi Minh City Vietnam and provides management services to one treatment center in Irvine California The business originated with the establishment of L’Ange Cosmetique Co Ltd in 2003 and SBCMG formerly…
SBC Medical Group Holdings Incorporated is a management company headquartered in Irvine California and Tokyo Japan that owns operates and provides management services to cosmetic treatment centers mainly in Japan The company also owns and operates one treatment center in Ho Chi Minh City Vietnam and provides management services to one treatment center in Irvine California The business originated with the establishment of L’Ange Cosmetique Co Ltd in 2003 and SBCMG formerly Aikawa Medical in 2017 for the purpose of providing management services to medical corporations and their clinics Over time the company expanded its franchise network under the Shonan Beauty Clinic brand to include 164 franchisee treatment centers in Japan The core activities involve delivering comprehensive support services such as advertising and marketing staff recruitment and training booking reservations construction and design medical equipment and supplies procurement licensure of intellectual property and technology IT software solutions for remote consultations and payment tools for franchisee clinics The company generates revenue primarily through its relationships with medical corporations that own the franchisee clinics and through the resale of medical supplies cosmetic products and equipment to those clinics
SBC Medical Group Holdings Incorporated generates revenue from several streams The largest portion comes from royalty income which is derived from licensing the Shonan Beauty Clinic brand and related trademarks to the medical corporations Procurement services revenue is earned by purchasing advertising services medical materials and equipment on behalf of the medical corporations and reselling them at a markup Management services revenue includes fees for loyalty program management labor supporting services function supporting services and management consulting services provided to the medical corporations Rental services revenue is obtained from operating leases and sales type leases of property and equipment Other revenues include accommodation services medicine dispensed sales brokerage services construction services pilot training services interest income and miscellaneous items In the six months ended June 30 2024 royalty income contributed 29 736 524 procurement services contributed 26 732 592 management services contributed 32 360 267 rental services contributed 7 071 114 and other revenues contributed 12 009 625 For the full year 2023 royalty income was 42 103 380 procurement services was 53 186 662 management services was 72 282 549 rental services was 7 336 768 and other revenues were 18 633 064 The company also receives fees under franchise agreements calculated as a percentage of clinic sales or as fixed monthly amounts per medical facility under service contracts with certain medical corporations
SBC Medical Group Holdings Incorporated holds a strong position within the cosmetic medical service management market particularly in Japan where it operates the largest network of franchisee clinics under the Shonan Beauty Clinic brand The company competes with other providers of aesthetic medical services and equipment such as Aesthetic Medispa Alma Lasers B Braun SE Cynosure Aesthetics Evolus Inc Galderma S A Genesis Biosystems Inc Inmode Ltd IRIDEX Corporation Lumenis Be Ltd Revance Therapeutics Inc Sientra Inc Sinclair Pharma Limited Stryker Corporation and Surgery Partners Its competitive advantages include a well established brand with over twenty years of history a comprehensive suite of management services that covers marketing staffing construction equipment procurement technology licensing and payment processing a high repeat customer rate exceeding ninety percent among franchisee clinics and the use of advanced simulation technologies such as virtual reality AI and 5G 6G to improve procedural accuracy and enable remote consultations The company’s ability to offer a one stop solution for franchisee clinics allows it to maintain stable revenue streams and to benefit from the growth of its franchise network Additionally the company’s focus on technology development and intellectual property licensing creates barriers to entry for competitors
The customer base of SBC Medical Group Holdings Incorporated consists primarily of individuals seeking cosmetic medical services such as surgery dermatology dentistry and related treatments The majority of these customers are individuals aged between twenty and forty representing approximately eighty five percent of the clinic customer base in 2023 Customers above forty account for the remaining fifteen percent The company’s directly owned and franchisee clinics serve these end users while its primary contractual customers are the medical corporations that own the franchisee clinics Specifically the company receives revenue from Medical Corporation Shobikai Medical Corporation Kowakai Medical Corporation Nasukai Medical Corporation Aikeikai Medical Corporation Jukeikai and Medical Corporation Ritz Cosmetic Surgery under franchise and service agreements Additionally the company has service contracts with Medical Corporation Association Furinkai and Medical Corporation Association Junikai for management consulting and operational support The Irvine California clinic and the Ho Chi Minh City Vietnam clinic also generate revenue from local individual patients who receive cosmetic treatments at those locations
Sectors:Healthcare · IndustrialsSector rationaleThe company's primary business is owning and operating cosmetic treatment centers and providing comprehensive management services to medical corporations that run clinics for surgery, dermatology, and dentistry. While it acts as a management company, its core revenue is derived from the delivery and support of medical services (Healthcare). A secondary sector of Industrials is justified because the company operates a substantial business line in procurement services, reselling medical supplies and equipment, and providing construction and design services to its clinic network.Industries:Healthcare ServicesHealthcarePrimaryThe company owns and operates cosmetic treatment centers in Vietnam and California, and provides comprehensive management services to a network of 164 franchisee clinics. These clinics deliver outpatient cosmetic medical services, including surgery, dermatology, and dentistry, which fits the description of healthcare services delivered in a clinic setting.Drug DistributionHealthcareSecondaryThe company generates significant revenue through procurement services, specifically by purchasing medical materials and equipment on behalf of medical corporations and reselling them at a markup.ConsultingIndustrialsSecondaryThe company provides management consulting services and operational support to medical corporations, such as Medical Corporation Association Furinkai and Medical Corporation Association Junikai, under specific service contracts.Classified using BQ-MICSCIK: 0001930313
Investment Thesis
▲ Bull case
SBC Medical’s recently launched SBC Wellness 2.0 platform represents a strategic pivot into the high-growth longevity market, projected to reach $2 trillion by 2035 with a CAGR exceeding 10% from 2026 to 2035, which remains underappreciated by investors focused solely on its legacy aesthetic healthcare business. The company’s existing footprint of 283 clinics and 6.63 million annual customer visits in Japan provides a unique data advantage, enabling the development of proprietary AI models trained on one of the largest aesthetic healthcare datasets in the country, creating a defensible moat that competitors cannot easily replicate without similar scale and historical patient interaction data. This data asset is not merely supplementary but foundational to the personalization engine of Wellness 2.0, which integrates blood biomarkers, imaging, and AI-driven recommendations—moving beyond superficial wellness offerings into clinically grounded performance medicine that commands premium pricing and higher retention. Management’s explicit intent to monetize through B2B corporate wellness contracts and high-margin self-pay services establishes a dual revenue stream with recurring characteristics, reducing customer acquisition costs over time and improving unit economics as scale increases, a transition that is already evident in Q4 FY25 where average revenue per customer rose 11% year-over-year to $316 despite flat top-line revenue. The lack of a clear market leader in Japan’s $34 billion domestic longevity market presents a first-mover opportunity for SBC Medical to capture share before entrenched competitors emerge, particularly given its strong brand recognition in aesthetic healthcare and proven ability to serve repeat premium clients across dermatology, orthopedics, and other specialties. Furthermore, the recent alliance with Daibi Medical Aesthetics in Shanghai signals early international traction for the Shonan Beauty Clinic brand, validating the scalability of its operational model beyond Japan and opening a pathway to tap into China’s rapidly growing medical aesthetics demand, which could accelerate global expansion faster than current guidance suggests. These factors collectively imply that the market is underestimating the margin expansion potential and sustainable growth trajectory of SBC Medical as it transitions from a transactional aesthetic provider to a data-driven, recurring-revenue longevity platform with global applicability.
SBC Medical’s recently launched SBC Wellness 2.0 platform represents a strategic pivot into the high-growth longevity market, projected to reach $2 trillion by 2035 with a CAGR exceeding 10% from 2026 to 2035, which remains underappreciated by investors focused solely on its legacy aesthetic healthcare business. The company’s existing footprint of 283 clinics and 6.63 million annual customer visits in Japan provides a unique data advantage, enabling the development of proprietary AI models trained on one of the largest aesthetic healthcare datasets in the country, creating a defensible moat that competitors cannot easily replicate without similar scale and historical patient interaction data. This data asset is not merely supplementary but foundational to the personalization engine of Wellness 2.0, which integrates blood biomarkers, imaging, and AI-driven recommendations—moving beyond superficial wellness offerings into clinically grounded performance medicine that commands premium pricing and higher retention. Management’s explicit intent to monetize through B2B corporate wellness contracts and high-margin self-pay services establishes a dual revenue stream with recurring characteristics, reducing customer acquisition costs over time and improving unit economics as scale increases, a transition that is already evident in Q4 FY25 where average revenue per customer rose 11% year-over-year to $316 despite flat top-line revenue. The lack of a clear market leader in Japan’s $34 billion domestic longevity market presents a first-mover opportunity for SBC Medical to capture share before entrenched competitors emerge, particularly given its strong brand recognition in aesthetic healthcare and proven ability to serve repeat premium clients across dermatology, orthopedics, and other specialties. Furthermore, the recent alliance with Daibi Medical Aesthetics in Shanghai signals early international traction for the Shonan Beauty Clinic brand, validating the scalability of its operational model beyond Japan and opening a pathway to tap into China’s rapidly growing medical aesthetics demand, which could accelerate global expansion faster than current guidance suggests. These factors collectively imply that the market is underestimating the margin expansion potential and sustainable growth trajectory of SBC Medical as it transitions from a transactional aesthetic provider to a data-driven, recurring-revenue longevity platform with global applicability.
Despite management’s optimism about structural headwinds being behind them, SBC Medical’s full-year FY25 revenue declined 15% to $174 million due to deliberate but impactful changes in franchise fee arrangements and business restructuring in 2024, signaling ongoing challenges in monetizing its clinic network that may persist beyond the stated timeline, especially as franchisee incentives remain misaligned under revised contracts that reduced corporate revenue streams while shifting more operational burden to local partners. The company’s reliance on related-party transactions remains a material concern, with accounts receivable from related parties totaling $27.5 million and finance lease receivables from related parties reaching $26.6 million combined across current and non-current portions as of December 31, 2025—figures that represent nearly 20% of total assets and raise questions about the arm’s length nature of these dealings, potential for hidden related-party risks, and the sustainability of cash flow generation if these relationships deteriorate or require restructuring. While net income grew 9% to $51 million and net income margin expanded to 29%, this improvement was largely driven by the non-recurrence of IPO-related stock-based compensation and prior-year impairment losses, not operational excellence, meaning the underlying profitability of the core business may be weaker than headline numbers suggest, particularly as EBITDA margin declined from 43% to 40% despite management framing it as a “normalized” run-rate, indicating ongoing pressure on operating efficiency. The SBC Wellness 2.0 initiative, while conceptually compelling, lacks concrete financial metrics—such as expected uptake rates, customer acquisition costs, or contribution margin targets—making it difficult to assess whether it will meaningfully offset the sluggishness in legacy segments, and its success hinges on unproven assumptions about consumer willingness to pay premiums for integrated aesthetic and longevity services in a market where preventative health offerings remain nascent and reimbursement pathways are unclear. Additionally, the company’s expansion into international markets via alliances like the one with Daibi Medical Aesthetics in Shanghai introduces execution risk, including regulatory hurdles, cultural adaptation challenges, and potential dilution of brand standards, all of which could undermine the premium positioning SBC Medical relies on to justify its pricing power, especially if early international ventures fail to deliver scalable returns or require significant management distraction from the core Japan business. These unresolved risks suggest that the market may be ignoring the fragility of SBC Medical’s transition and overestimating the speed and certainty of its shift toward higher-margin, recurring revenue models.
Despite management’s optimism about structural headwinds being behind them, SBC Medical’s full-year FY25 revenue declined 15% to $174 million due to deliberate but impactful changes in franchise fee arrangements and business restructuring in 2024, signaling ongoing challenges in monetizing its clinic network that may persist beyond the stated timeline, especially as franchisee incentives remain misaligned under revised contracts that reduced corporate revenue streams while shifting more operational burden to local partners. The company’s reliance on related-party transactions remains a material concern, with accounts receivable from related parties totaling $27.5 million and finance lease receivables from related parties reaching $26.6 million combined across current and non-current portions as of December 31, 2025—figures that represent nearly 20% of total assets and raise questions about the arm’s length nature of these dealings, potential for hidden related-party risks, and the sustainability of cash flow generation if these relationships deteriorate or require restructuring. While net income grew 9% to $51 million and net income margin expanded to 29%, this improvement was largely driven by the non-recurrence of IPO-related stock-based compensation and prior-year impairment losses, not operational excellence, meaning the underlying profitability of the core business may be weaker than headline numbers suggest, particularly as EBITDA margin declined from 43% to 40% despite management framing it as a “normalized” run-rate, indicating ongoing pressure on operating efficiency. The SBC Wellness 2.0 initiative, while conceptually compelling, lacks concrete financial metrics—such as expected uptake rates, customer acquisition costs, or contribution margin targets—making it difficult to assess whether it will meaningfully offset the sluggishness in legacy segments, and its success hinges on unproven assumptions about consumer willingness to pay premiums for integrated aesthetic and longevity services in a market where preventative health offerings remain nascent and reimbursement pathways are unclear. Additionally, the company’s expansion into international markets via alliances like the one with Daibi Medical Aesthetics in Shanghai introduces execution risk, including regulatory hurdles, cultural adaptation challenges, and potential dilution of brand standards, all of which could undermine the premium positioning SBC Medical relies on to justify its pricing power, especially if early international ventures fail to deliver scalable returns or require significant management distraction from the core Japan business. These unresolved risks suggest that the market may be ignoring the fragility of SBC Medical’s transition and overestimating the speed and certainty of its shift toward higher-margin, recurring revenue models.